Latest news
Multidisciplinary Co-Management of Patients Receiving Radioligand Therapy - Phillip Koo & Neha Vapiwala - UroTodayUroToday · Fri, 07 Aug 2026 22:29:26 GMTPSMA PET Interpretation in Biochemical Recurrence After Prostate Cancer Treatment - Steve Cho - UroTodayUroToday · Fri, 07 Aug 2026 21:54:26 GMTPractical Implementation of the EMBARK Regimen for High-Risk Biochemical Recurrence - Zachary Klaassen - UroTodayUroToday · Fri, 07 Aug 2026 21:06:43 GMTTALAPRO-3 Results and the Role of Upfront PARP Inhibition in APMS Prostate Cancer - Andrew Armstrong - UroTodayUroToday · Fri, 07 Aug 2026 19:52:20 GMTGenomic Testing in Metastatic APMR Prostate Cancer and Its Treatment Implications - Rana McKay - UroTodayUroToday · Fri, 07 Aug 2026 05:04:08 GMTUSPCC 2026: Point-Counterpoint 3: Treatment of Metastatic APMN/S Prostate Cancer: Metastasis Directed Radiation - UroTodayUroToday · Fri, 07 Aug 2026 01:04:09 GMTApproval of Pluvicto® for Metastatic Hormone-Sensitive Prostate Cancer - Oliver Sartor - UroTodayUroToday · Thu, 06 Aug 2026 19:44:56 GMTCAPItello-281 and the PTEN-Deficient Subset of Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans - UroTodayUroToday · Thu, 06 Aug 2026 17:23:13 GMT